Search: ARK™ Oxcarbazepine Metabolite Assay ARK™ Oxcarbazepine Metabolite Assay Specialty Diagnostix and ARK Diagnostics introduce the first homogeneous immunoassay for the Therapeutic Drug Monitoring of the Oxcarbazepine Metabolite 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide (or 10-Monohydroxy derivative [MHD] of Oxcarbazepine) in human serum. The ARK™ Oxcarbazepine Metabolite Assay provides a fast, sensitive and convenient alternative to the more time-consuming chromatographic methods. Assay Characteristics A convenient and simple method for the monitoring of Oxcarbazepine Metabolite Excellent precision and recovery Highly specific and sensitive assay for the detection of Oxcarbazepine Metabolite even in trough level concentrations No cross-reactivity with structurally unrelated AEDs No time-consuming sample preparation and extraction Liquid, stable, ready-to-use reagent, calibrators and controls Application protocols for all major clinical chemistry analyzers Background Oxcarbazepine is used in the treatment of epilepsy, anxiety and mood disorders as well as benign motor tics. In addition, it seems to be effective in patients with bipolar disorders. Both the chemical structure and therapeutic activity of Oxcarbazepine are similar to Carbamazepine, but with a considerably reduced potential for negative side effects. Oxcarbazepine is a next generation anti-convulsant and mood-stabilizing agent and, similar to Eslicarbazepine acetate, a so called pro-drug that is metabolized to the active, clinically relevant metabolite MHD, which has an (S)-(+)- and an (R)-(-)-enantiomer. However, only the pharmacokinetics of the racemate are actually reported. Serum concentrations of 3 to 35 µg/mL of the active Oxcarbazepine Metabolite are associated with a clinically effective control of partial seizures. Adverse effects may occur at concentrations exceeding 35 µg/mL. Therapeutic Drug Monitoring is justified when changes are expected that might alter the clearance of the Oxcarbazepine Metabolite. These may include pregnancy, the concomitant use of liver enzyme inducing medication or renal insufficiency. Download PDF European Headquarters Specialty Diagnostix GmbH, Sailerwöhr 16, D-94032 Passau, +49 (0)851 98849300, info@specialtydiagnostix.de Copyright 2021 by Specialty Diagnostix GmbH AGB Imprint Privacy Statement Sitemap